Dermapharm Holding SE expands capacity to produce COVID-19 vaccine

 Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute

high double-digit million EUR in sales in 2021 
Grünwald, February 12, 2021 - Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of off-patent branded 
pharmaceuticals for selected therapeutic areas, expects the collaboration with BioNTech SE, Mainz, Germany, for the 
production of the Covid-19 vaccine Comirnaty^(R) to contribute a high double-digit million EUR amount to the consolidated 
sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production 
approved by the Dermapharm Management Board today. Among other things, it includes the establishment of additional 
production capacities at the Reinbek site, which are scheduled to go into operation in May 2021. 
In September 2020, Dermapharm signed a cooperation and supply agreement with BioNTech SE to support the production of 
the vaccine Comirnaty^(R). At the main production site at mibe GmbH Arzneimittel in Brehna, Dermapharm has expanded 
production and special storage capacities for the formulation as well as the aseptic filling, packaging (fill & finish) 
and storage of the vaccine. The vaccine has been produced in Brehna since the beginning of October 2020. 
Due to the high demand for the vaccine, additional production capacities are now being established at Allergopharma 
GmbH & Co. KG, a subsidiary of Dermapharm, at the Reinbek site. Initial personnel are already being recruited and 
employees are being trained in Brehna in order to be able to start vaccine production as soon as possible. 
"At Allergopharma, we have the necessary prerequisites and also the internal know-how to set up vaccine production at 
short notice. We will build up capacities in Reinbek that significantly exceed our production capacities in Brehna. We 
owe the short-term implementation in particular to the constructive cooperation with BioNTech, our suppliers and 
employees, and the responsible authorities," continues Dr. Feldmeier. "We are very proud and highly motivated to be 
able to make an important contribution to combating the pandemic with this partnership. Our high flexibility for the 
cooperation with BioNTech proves once again the necessity to maintain production capacities for pharmaceuticals at the 
location Germany / Europe." 

https://www.marketscreener.com/quote/stock/DERMAPHARM-HOLDING-SE-40718509/news/PRESS-RELEASE-Dermapharm-Holding-SE-expands-capacity-to-produce-COVID-19-vaccine-and-plans-for-vac-32427332/